State Street's passive stake increase is routine for a large index fund manager. Monitor the next 13F filing for any material changes in institutional positioning, but this filing alone does not signal a shift in investment thesis.
SNDX drugs
SNDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $9.49entry
- T+1 · 6d ago +1.05%α −0.27% · $9.59
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp filed a Schedule 13G disclosing a 5.2% passive stake in Syndax Pharmaceuticals as of September 30, 2026, representing 4,653,172 shares. This is an amendment to its prior 13G filed in August 2026, showing a slight increase in holdings. The filing confirms a passive investment intent with no control or activist purpose.
Key Financial Metrics
Key Facts
- State Street Corp disclosed beneficial ownership of 4,653,172 shares of Syndax Pharmaceuticals common stock
- Stake represents 5.2% of shares outstanding as of September 30, 2026
- Filing is an amendment to a prior 13G filed August 7, 2026
- State Street certifies passive investment intent under Rule 13d-1(b)
- State Street is a top institutional holder per Q2 2026 13F data with $124M position
Financial Impact
State Street's stake is valued at approximately $44.6M based on the current $858M market cap and 5.2% ownership
Risk Factors
- No activist intent or control purpose disclosed
- Passive 13G filing; no imminent catalyst from this holder
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000728 |
| Document: 0000093751-26-000728-index.html | 0000093751-26-000728 |
| Document: 0000093751-26-000728.txt | 0000093751-26-000728 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers